Memento Medicines

Memento Medicines is a biotech company advancing novel antibody therapies for ophthalmology.

Founded in 2026 as the fifth subsidiary of Sera Medicines, a biologics-focused antibody accelerator formed in collaboration with RA Capital, the company is committed to developing new therapies for patients living with retinal diseases.

Memento's lead program, MMT-205, is a potential best-in-class bispecific antibody that activates Tie2 and inhibits VEGF, in development for neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME).